Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients with Non-Small Cell Lung Cancer

Trapé, Jaume; Olaguer, Joaquim Pérez de; Buxó, J; López, Laura

doi:10.1373/clinchem.2004.040659

Cited by 23 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, a clearer description of population such as age and racial distribution, nutritional status, presence of peritoneal carcinomatosis and ascites, presence of infection disease, exclusion of autoimmune disease or another malignancies (such as metastatic ovarian cancers from gastrointestinal system) could be very important for the evaluation of biomarker levels [46]–[49]. Second, natural biological variation of certain markers and individual biological variation over time should also be considered as the associated variability could induce a number of assay measurement error by false-positive results [50], [51]. For example, the inherent intra-individual biological variation in CA125 was greater in premenopausal than in postmenopausal females [52].…”

Section: Discussionmentioning

confidence: 99%

Development of Multiplexed Bead-Based Immunoassays for the Detection of Early Stage Ovarian Cancer Using a Combination of Serum Biomarkers

et al. 2012

View full text Add to dashboard Cite

CA125 as a biomarker of ovarian cancer is ineffective for the general population. The aim of this study was to evaluate multiplexed bead-based immunoassay of multiple ovarian cancer-associated biomarkers such as transthyretin and apolipoprotein A1, together with CA125, to improve the identification and evaluation of prognosis of ovarian cancer. We measured the serum levels of CA125, transthyretin, and apolipoprotein A1 from the serum of 61 healthy individuals, 84 patients with benign ovarian disease, and 118 patients with ovarian cancer using a multiplex liquid assay system, Luminex 100. The results were then analyzed according to healthy and/or benign versus ovarian cancer subjects. When CA125 was combined with the other biomarkers, the overall sensitivity and specificity were significantly improved in the ROC curve, which showed 95% and 97% sensitivity and specificity, respectively. At 95% specificity for all stages the sensitivity increased to 95.5% compared to 67% for CA125 alone. For stage I+II, the sensitivity increased from 30% for CA125 alone to 93.9%. For stage III+IV, the corresponding values were 96.5% and 91.6%, respectively. Also, the three biomarkers were sufficient for maximum separation between noncancer (healthy plus benign group) and stage I+II or all stages (I−IV) of disease. The new combination of transthyretin, and apolipoprotein A1 with CA125 improved both the sensitivity and the specificity of ovarian cancer diagnosis compared with those of individual biomarkers. These findings suggest the benefit of the combination of these markers for the diagnosis of ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of Multiplexed Bead-Based Immunoassays for the Detection of Early Stage Ovarian Cancer Using a Combination of Serum Biomarkers

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Any variation of the aforementioned factors influences the detection of tumor markers. [8] Therefore, the clinical significance of tumor markers only indicates their correlation with tumor, but not specificity. These tumor markers are specific to an organ, not to a type of tumor.…”

Section: Serologic Monitoring Indexesmentioning

confidence: 99%

“…The biomarkers in circulating blood are often associated with biomarkers of cell morphology; the latter includes immunohistochemical markers (particularly correlated with lowly differentiated tumors), cell surface markers of hematologic tumor, and biomarkers generated by genetic abnormality, such as proto-oncogene, anti-oncogene, and gene products. [8] The level of tumor markers is restored to the normal range when the body completely recovers, but still remains at a higher degree compared with the normal stage if the disease is just partly alleviated or progresses. [8] In clinical practice, serum tumor markers are often combined with imaging examination to monitor the effect of chemotherapy and determine tumor recurrence.…”

Section: Introductionmentioning

confidence: 99%

“…[8] The level of tumor markers is restored to the normal range when the body completely recovers, but still remains at a higher degree compared with the normal stage if the disease is just partly alleviated or progresses. [8] In clinical practice, serum tumor markers are often combined with imaging examination to monitor the effect of chemotherapy and determine tumor recurrence.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Advances in the study of serum tumor markers of lung cancer

Kang

2014

J Can Res Ther

View full text Add to dashboard Cite

Lung cancer is among the most prevalently occurring carcinomas worldwide, and reducing lung cancer mortality depends on early detection, diagnosis, and treatment. Given the rapid development of molecular biology and modern techniques for diagnosis and treatment, the study of serum tumor markers has gained extensive application in early diagnosis, treatment effect monitoring, and prognosis evaluation. Serum tumor markers possess the advantages of easy detection, noninvasive operation, and cost-effectiveness. This article reviews the progress in the study of serum tumor markers of lung cancer.

show abstract

“…Although this option has not been practically considered for CA-125, the available studies on the estimation of biological variability for this marker have strongly supported this hypothesis. 23,62,63 In evaluating literature on biologic variability, concerns may arise on the study results often supporting the need for revaluating available information. 64,65 Basically, a well-defined study protocol to preclude marker homeostatic disturbances as well as to minimize pre-analytical sources of variability is recommended.…”

Section: Unbiased Interpretation Of Marker Changesmentioning

confidence: 99%

Is serum human epididymis protein 4 ready for prime time?

Ferraro

Panteghini

2013

Ann Clin Biochem

View full text Add to dashboard Cite

The National Institute for Health and Clinical Excellence (NICE) guidelines have sparked hot debate regarding the role of carbohydrate antigen 125 (CA-125) for ovarian cancer (OC) detection. Recent literature and evidence calls into question the use of CA-125 in diagnostic algorithms, given the better performance of human epididymis protein 4 (HE4) vs. CA-125 to rule OC. This is an important consideration since combined measurements are not cost-effective. The quality of this evidence is, however, threatened by important gaps related to study design, enrolled populations and analytical issues. For instance, despite the clinical need to prioritize the evaluation of biomarker performance in early stage tumours, sound evidence on this cannot be provided. In addition, results should be cautiously interpreted due to wide differences in the type of employed assays and in adopted diagnostic thresholds for HE4. Comparability among results obtained by different commercially available HE4 assays, together with an objective establishment of analytical goals is essential for the optimal clinical application of this marker.

show abstract

Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients with Non-Small Cell Lung Cancer

Cited by 23 publications

References 19 publications

Development of Multiplexed Bead-Based Immunoassays for the Detection of Early Stage Ovarian Cancer Using a Combination of Serum Biomarkers

Development of Multiplexed Bead-Based Immunoassays for the Detection of Early Stage Ovarian Cancer Using a Combination of Serum Biomarkers

Advances in the study of serum tumor markers of lung cancer

Is serum human epididymis protein 4 ready for prime time?

Contact Info

Product

Resources

About